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Abstract
Objective To develop a novel prognostic indicator for use in patients
with advanced cancer that is significantly better than clinicians’ estimates
of survival.
Design Prospective multicentre observational cohort study.
Setting 18 palliative care services in the UK (including hospices, hospital
support teams, and community teams).
Participants 1018 patients with locally advanced or metastatic cancer,
no longer being treated for cancer, and recently referred to palliative
care services.
Main outcome measures Performance of a composite model to predict
whether patients were likely to survive for “days” (0-13 days), “weeks”
(14-55 days), or “months+” (>55 days), compared with actual survival
and clinicians’ predictions.
Results On multivariate analysis, 11 core variables (pulse rate, general
health status, mental test score, performance status, presence of
anorexia, presence of any site of metastatic disease, presence of liver
metastases, C reactive protein, white blood count, platelet count, and
urea) independently predicted both two week and two month survival.
Four variables had prognostic significance only for two week survival
(dyspnoea, dysphagia, bone metastases, and alanine transaminase),
and eight variables had prognostic significance only for two month
survival (primary breast cancer, male genital cancer, tiredness, loss of
weight, lymphocyte count, neutrophil count, alkaline phosphatase, and
albumin). Separate prognostic models were created for patients without
(PiPS-A) or with (PiPS-B) blood results. The area under the curve for
all models varied between 0.79 and 0.86. Absolute agreement between
actual survival and PiPS predictions was 57.3% (after correction for
over-optimism). The median survival across the PiPS-A categories was
5, 33, and 92 days and survival across PiPS-B categories was 7, 32,
and 100.5 days. All models performed as well as, or better than,
clinicians’ estimates of survival.
Conclusions In patients with advanced cancer no longer being treated,
a combination of clinical and laboratory variables can reliably predict
two week and two month survival.
Introduction
Patients with advanced cancer and their carers often wish to
know how long they have left to live.
1 2 Accurate prognostic
informationcanallowpatientsadequatetimetopreparefortheir
impending death.
3 Qualitative studies show that patients in
palliative care want to be given honest and accurate prognostic
information but that this information needs to be shared
sensitivelyandinawaythatrespectspatients’desiretomaintain
hope.
4 5
Prognosticinformationisalsoimportantforclinicians.Realistic
survival estimates can inform decisions about the
appropriateness of medical interventions and the timing of
referral to specialist palliative care services or admission to a
hospice. Clinicians’ predictions are routinely used to prioritise
patients who are suitable for inclusion in programmes such as
the Gold Standards Framework,
6 to determine which patients
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Research
RESEARCHare suitable for “fast-tracking” arrangements for referral to
community care, and to determine eligibility for clinical trials.
Clinicians’ predictions of survival are inaccurate and
over-optimistic.
7 Moreover, their estimates are affected by
factors such as training, experience, seniority, and level of
acquaintance with the patient.
8 For these reasons, a clinician’s
prediction is not a very reliable or robust method of predicting
survival. None the less, clinicians’ predictions are widely used,
and any attempt to produce a more standardised answer to the
question “How long have I got?” should be able to show that it
is at least as reliable as this approach.
Previous studies have identified several clinical and laboratory
variables that predict survival in patients with advanced
cancer.
9 10 Prognostic tools have been created by using scoring
systems derived from combinations of these variables.
11 Some
of these tools include clinicians’ subjective estimates.
12 13 Some
rely on observers’ ratings of clinical variables but do not
considertheaddedvalueofincludinglaboratorydata.
14 15Some
tools include laboratory data but consequently can be applied
only when such data are available.
13 16 17 Some tools were
developed by using only competent patients,
13 16 17 whereas
confused patients were included in the process of scale
development of other tools.
14 18 One important criticism of
existing tools is that their performance has not been
“benchmarked” against clinicians’ predictions of survival,
making it difficult to judge the usefulness of these scales in
clinical practice.
We sought to develop a prognostic tool that could be easily
applied in clinical practice. Patients with advanced cancer are
oftenfrail,vulnerable,orconfused.Manypatientsareunwilling
to undergo further procedures (even blood tests). To produce a
practicalprognostictool,weaimedtocreateacompositescoring
system that could be used in both competent and incompetent
patients and regardless of whether laboratory data were
available. We wanted to develop a scoring system that was
applicable across a range of palliative care settings (hospice,
hospital, and community). Moreover, we wanted to produce a
scale that did not rely on clinicians’ estimates of survival but
was at least as accurate as their best predictions.
Methods
Study settings
This was a multicentre study involving 18 palliative care
services across England. Participating units included hospital
support teams, hospice inpatient units, day centres, and
community palliative care teams. We collected data between
March 2006 and August 2009 and followed up all patients for
a minimum of three months after recruitment.
Patient population
Patients were eligible to participate in this study if they had
been newly referred to the relevant palliative care service with
a diagnosis of advanced (locally extensive or metastatic),
incurable cancer. Eligible patients were no longer receiving
active treatment for cancer, and no further disease modifying
treatmentwasplanned.Patientswithhormonesensitivetumours
who were still receiving hormone therapy but who had
developedhormoneresistantdiseasewereeligibletoparticipate,
as were patients receiving palliative radiotherapy that was not
expectedtoprolongsurvival(forexample,forbonemetastases).
Both competent and incompetent patients were eligible. We
restricted study assessments in incompetent patients to
observers’ratingsofclinicalstatusandextractionofinformation
from case notes (questionnaires and blood tests were not done
in incompetent patients).
Study assessments
Systematicreviewsofstudiesinvolvingpatientswithadvanced
cancer identified several variables with good a priori evidence
of prognostic utility.
9 10 These variables formed the basis for
our assessments in study participants.
Observer rated symptom checklist, performance
status, and global health status
In consultation with the clinical team, a researcher completed
a checklist of the following symptoms: pain, breathlessness at
rest, loss of appetite, dry mouth, difficulty swallowing, and
tiredness. We recorded these symptoms as being either present
or absent. We recorded the patient’s Eastern Co-operative
Oncology Group (ECOG) performance status.
19 ECOG scores
varybetween0and4(0=normalfunctionalabilities,4=confined
to a bed or chair and requires all care). We recorded global
health status by using a study specific seven point scale
(1=extremely poor health, 7=normal health).
Clinical observations
We measured weight and height when possible and asked
patients or their carers whether weight loss had occurred over
the previous month. We recorded pulse rate and the presence
of clinically apparent dependent pitting oedema or ascites.
Abbreviated mental test score
We used the abbreviated mental test score to assess cognitive
status.
20Althoughnotacomprehensiveassessmentofcognitive
function, this 10 item scale is often used in clinical practice to
screen patients for confusion. We chose it for its ease of
administration and because it reflects the type of assessment
commonlydoneinclinicalpractice.Forethicalreasons,patients
who were deemed to be incompetent were not interviewed for
this study but were attributed a score of 0.
Clinician’s prediction of survival
We asked clinicians to predict the survival of the patient by
using one of four categories: “days” (that is, less than 14 days),
“weeks” (from two weeks to less than eight weeks), “months”
(from two months to less than 12 months), and “years” (12
months or more). We chose these categories as they seemed to
have the greatest face validity among palliative care
practitioners. Clinicians seldom make precise predictions, and
asking clinicians to predict survival to the nearest day or week
would have resulted in spuriously accurate prognostic
predictions. Moreover, the Department of Health’s Prognostic
Indicator Guidance, issued as part of the Gold Standards
Framework,
6recommendsthesecategories.Researchersobtained
a clinician’s estimate independently from both a doctor and a
nurse. When these estimates agreed, we also took this as the
“agreed multi-professional estimate.” When a discrepancy
existed between the clinicians, we asked them to discuss the
case and arrive at an explicitly agreed estimate. Because only
a small number of participants were estimated to be likely to
survive for “years,” we included these patients with those with
an estimated survival of “months” in all analyses.
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RESEARCHDemographic, disease related, and treatment
related variables
We recorded the age, sex, ethnicity, marital status, normal
residence, diagnosis, and extent of disease (site of primary
tumour and presence and sites of metastatic disease). We also
recorded information on the extent of previous treatments, the
time since the original diagnosis, and the time since the last
treatment for cancer had been administered. We collected data
on survival from entry to the study by flagging all patients for
mortality with the NHS Information Centre.
Comorbidity
We recorded comorbidity by using the Charlson Co-morbidity
Index.
21 This provides a measure of the overall extent of
comorbid disease by using a four point scoring system (0=no
comorbid diseases, 3=presence of multiple or severe
comorbidity).
Laboratory variables (when available)
We asked all competent patients who agreed to participate in
the study to provide a specimen of blood for analysis of
haematologicalandbiochemicalparameters.Wedidnotrequire
incompetent patients to provide a blood specimen for analysis;
however,wheresuchresultswereavailablefromclinicalpractice
(withinfourdaysofstudyentry),weenteredthemintothestudy
database and included them in the analysis.
Additional data
Weaskedcompetentpatientstocompletethesymptomchecklist,
ECOG performance status, and global health status. We also
asked competent patients whether they wished to estimate their
own prognosis. We did not use these data in the generation of
the prognostic scores reported here, and they will be reported
elsewhere.
Procedures
We maintained a screening log of all clinical referrals to
participating units. We identified eligible competent patients
and, with the agreement of the clinical team, provided them
with information and invited them to participate. We similarly
informedtherelativesorcarersofeligibleincompetentpatients
and asked them for assent.
Weassessedstudyparticipantsontwooccasionsoneweekapart:
blood tests were not repeated specifically for the study, as this
was judged to be too onerous for participants. We used only
data from the baseline assessment to construct the prognostic
tools described in this paper, and data from the second
assessment are not presented. We calculated survival (in days)
from the date of study entry.
Statistical methods
We constructed a database and checked data for accuracy and
missing values. We included in the model building analysis
those variables that we deemed a priori to be predictors of
survival on the basis of clinical knowledge and for which only
small amounts of data were missing (<6% of data missing for
all included variables except C reactive protein, for which 13%
ofdataweremissing).Weincludedparticipantswithincomplete
data in the analysis by using multiple imputation by chained
equations,
22 23 with 20 imputations. No consensus exists about
the best method for selecting variables for inclusion in a
predictive tool, but backwards elimination is generally the
preferred method, and we chose it for this analysis.
24 To reduce
the computational burden, we used single imputation for the
initialstagesofbackwardselectionwithacut-offPvalueof0.3
before completing the selection of variables by using multiple
imputation with a cut-off P value of 0.05. We did this analysis
for outcomes at two weeks’ (14 day) and two months’ (56 day)
survivalinboththefulldataset(PiPSmodelA)andtherestricted
dataset obtained from participants for whom blood results were
available (PiPS model B), giving four models in all. An
alternative modelling strategy would have used a single ordinal
logisticmodel,butthedatadidnotsatisfytheproportionalodds
assumption, evident from the difference between the two week
and two month models for both PiPS models A and B. We
estimated the level of over-optimism in each model by using a
bootstrap technique,
22 25-27 in which we drew bootstrap samples
from the original dataset and then repeated the complete model
selectionproceduretodevelopanewmodel.Wethenestimated
optimismasthedifferenceinperformancebetweenthebootstrap
sample and the original dataset. We used the average of the
optimism over all 1000 bootstraps as a correction factor for the
performance of the original model based on the full dataset.
We assessed the goodness of fit of the models by using the area
underthereceiveroperatingcharacteristicscurve.Wecombined
themodels’predictionsforthetwoweekandtwomonthcut-off
points to produce a categorical prediction of survival (“days,”
“weeks,” or “months/years”) that could be directly compared
with clinician’s estimates. One limitation of fitting two logistic
models is that some participants may be classified as having a
survivalofbothlessthantwoweeksandmorethantwomonths.
Thishappenedononlyoneoccasion,andweclassifiedthiscase
as having a survival between two weeks and two months. We
used linear weighted κ to compare the performance of the
clinicians with that of the models (after adjustment for
over-optimism), as this averages the κ coefficients for the two
week and two month threshold.
28 We plotted Kaplan-Meier
survival curves for each of the three risk groups (“days,”
“weeks,” and “months+”) and used Harrel’s C statistic to
measure concordance.
29
Results
Duringthestudyperiod,7017consecutiveeligiblepatientswere
identified across the 18 participating palliative care services.
The research team was able to access only 2401 of the eligible
patients (fig 1⇓). The most common reason for failure to access
patients was discharge or death before being approached by the
research team. The clinical team denied the researchers access
to eligible patients on 1102 occasions, because they judged that
involvement in a research study would prove to be too
distressingforpatientsortheircarers.Ofthe2401patients/carers
whowereapproachedbytheresearchteam,1023(43%)agreed
to participate (780 competent, 243 incompetent patients). No
significant differences in age, sex, or distribution of diagnoses
existed between recruited patients and the eligible patients who
werenotrecruited.Fivepatientswereremovedfromthedataset:
one was subsequently diagnosed as having a new primary
tumour and no longer met the eligibility criteria, two chose to
withdraw, and two were recruited twice in error. The final
sample thus consisted of 1018 participants. Tables 1⇓ and 2⇓
show the characteristics of the study sample. The median
survival of the group was 34 days.
Development of PiPS-A and PiPS-B models
WedevelopedthePiPS-Amodelsbyusingthecoredatasetthat
was collected from all participants (both competent and
incompetent).Wedevelopedseparatemodelstopredictsurvival
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RESEARCHof two weeks (14 days) or more (PiPS-A14) and to predict
survival of two months (56 days) or more (PiPS-A56). We
developed the PiPS-B models by using data from only those
participants for whom blood results had also been obtained.
Again, we developed separate models for predicting two week
(PiPS-B14)andtwomonth(PiPS-B56)survival.Tables3⇓and
4⇓showtheresultsofthebackwardstepwiselogisticregression.
Performance of models and cross validation
The areas under the curve of the four models all exceeded 0.79
(tables3⇓and4⇓),whichshowsgooddiscrimination.
24Logistic
regression models provide estimates of survival at specified
“cut-off points.” However, clinicians are not usually interested
injustwhetherapatientwillsurviveformorethan,forexample,
two weeks (the information provided by PiPS-A14). For this
reason,theclinicalquestionisoftenframedintermsofwhether
thepatientisexpectedtosurvivefor“days”(<14days),“weeks”
(14-56 days), or “months/years” (>56 days). To consider this
question, we combined the PiPS-A14 and PiPS-A56 models
(and the PiPS-B14 and PiPS-B56 models) to predict whether a
patient was likely to survive for more than two weeks but less
than two months. We then compared these predictions with the
multi-professional estimates of survival (tables 5⇓ and 6⇓).
Using this more demanding measure of clinical utility, the
PiPS-A models performed at least as well as the clinicians
(PiPS-A predictions correct on 59.6% of occasions and
multi-professional predictions correct on 57.5%). The PiPS-B
modelsperformedsignificantlybetterthandideitherthedoctors
(61.5% v 52.6%; P=0.0135) or the nurses (61.5% v 52.3%;
P=0.012) but were not significantly better than the
multi-professional estimate (61.5% v 53.7%; P=0.188).
Using the PiPS-A models (fig 2⇓), the median survival of
patients predicted to survive “days” was five days, that of those
predicted to survive “weeks” was 33 days, and that of those
predicted to survive “months+” was 92 days (Harrell’s
concordance (C) statistic=0.69). For the PiPS-B models (fig
3⇓), the equivalent median survival was seven days, 32 days,
and 100.5 days (C=0.67).
Discussion
Inthislarge,prospective,multicentrestudy,wehavedeveloped
and validated four prognostic models for predicting survival in
palliativecarepatientswithadvancedcancer.Thesemodelsare
able to identify reliably those patients with expected prognoses
of“days,”“weeks,”or“months/years”andcanbeusedineither
competent or incompetent patients and in circumstances when
blood results are available and when additional investigations
wouldbeinappropriate.Whencombined,theprognosticmodels
were at least as good as a multi-professional clinical estimate
of survival; when blood results are available, the models were
significantlybetterthaneitheradoctor’soranurse’sprediction
(but not a multi-professional estimate).
Strengths of study
Ourstudyhadseveralstrengths.Theprimaryaimwastodevelop
a prognostic scoring system that was significantly better than
(and independent of) clinicians’ predictions of survival. No
previous studies have attempted to “benchmark” their
performance against current best clinical practice in this way.
As a result, we have been able to show that the PiPS scores are
better than the best uni-professional specialist clinical
predictions of survival. All of the variables assessed as part of
thePiPSstudywerepreviouslyidentifiedinsystematicreviews
as being of likely prognostic significance,
9 10 and the final
variables included in our models have been found to be reliable
predictorsofsurvivalinalargeheterogeneousgroupofpatients
withadvancedcancerinavarietyofdifferentsettings(hospital,
hospice, and community). This supports the generalisability of
our results. Our decision to combine the prognostic models to
producea“categorical”estimateofsurvival(intermsof“days,”
“weeks,” or “months+”) can also be considered to be a strength
ofthestudy.TheresultingPiPSalgorithmsproduceanestimate
of survival that is clinically meaningful and that can be directly
compared with clinicians’ own estimates.
Weaknesses of study
Our study also had several limitations. Although we tried to
study all evaluable patients, some were not accessible because
of “gatekeeping” by clinical staff. The phenomenon of
“gatekeeping” is a common problem in palliative care
studies,
30 31 reflecting a desire by clinical staff to protect patients
from the perceived burden of involvement in clinical studies.
Such selective recruitment may distort findings if it renders the
research sample unrepresentative of the population of interest.
Aware that this was a potential limitation to our study, we
investedconsiderableeffortinaccuratelydocumenting“flows”
ofpatientsthroughtheresearchprocess.Mostpreviouspalliative
prognostic studies have not needed to rely on patients’ consent
before recruitment or have reported only the results from
“evaluable” patients.
12 13 18 32 In contrast, we recorded data on
all referrals to participating units and attempted to document
the reasons why we could not evaluate some patients.
The fact that many potentially eligible patients for our study
were non-evaluable was disappointing, but this reflects the
reality of dealing with patients who have advanced disease. We
didnotfindanysignificantdifferencesinage,sex,ordiagnoses
between evaluable and non-evaluable patients. The most
commonreasonswhypatientswerenotevaluatedwerethatthey
were under the care of the palliative care team for only a very
shorttime(n=1899),soinsufficienttimewasavailabletoobtain
informed consent; that the healthcare team deemed that
discussion of prognosis would be too distressing (n=1102); or
that the patient declined the offer from the healthcare team to
talktoaresearcheraboutthestudy(n=578).Allofthesereasons
for failure to evaluate patients with the PiPS score also pertain
to “real world” situations. We could therefore argue that the
sample of patients recruited to our study is representative of the
sort of patients who would be offered a PiPS evaluation in
clinical practice.
Another potential limitation of our study is that the results have
notyetbeenevaluatedinanindependentpopulation.Developing
prognostic models and testing them in the same population is
known to produce over-optimism. The usual approach to cross
validation is to develop the model in one half of the dataset (the
training set) and to validate it in the other half (the testing set).
Bootstrapping is an alternative cross validation technique that
maximisesthestudydata.Itisare-samplingprocedureinvolving
taking repeated samples (with replacement) from the dataset.
The bootstrap validation in this study allowed us to “correct”
for over-optimism in the development of the models and still
to show that the PiPS predictions are robust. However, external
validation in a separate cohort is still needed to confirm the
predictive accuracy of the proposed models.
Our study was limited to determining the statistical accuracy
of the PiPS prognostic algorithms. We did not assess whether
introduction of the PiPS scores into clinical practice results in
any demonstrable improvements in patient care. Future studies
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d4920 doi: 10.1136/bmj.d4920 Page 4 of 15
RESEARCHshould include an assessment of the clinical utility as well as
the statistical accuracy of the PiPS scores.
Relation to other studies
The PiPS models offer some definite advantages over existing
methods of predicting survival in this population of patients.
The most common method of prognostication is a clinician’s
prediction of survival. However, as this is a subjective
assessment, predictions cannot be standardised across sites or
over time. This lack of consistency means that relying on
clinicians’ predictions of survival is not an entirely suitable
method of identifying patients for inclusion in clinical trials,
forreferraltospecialistservices,orfordiscussionswithpatients
and families about the future. The PiPS-A scoring algorithms,
althoughnomoreaccuratethanamulti-professionalprognostic
estimate, do provide an objective and repeatable output and
wouldattheveryleastprovideanexcellentreproduciblemethod
forassessingeligibilityforresearchstudies.Whenbloodresults
areavailable,thePiPS-Bscoresaresignificantlymoreaccurate
than either a doctor’s or a nurse’s estimate and thus could
provide a robust rationale for making many decisions about
treatment.
Otherthanclinicians’estimates,themostwidelystudiedmethod
of predicting survival in patients with advanced cancer is
probably the palliative prognostic score.
12 13 This score is
calculatedfromsixvariables,oneofwhichisitselfaclinician’s
prediction. Each variable is allotted a “partial score” that
dependsonthesizeoftheregressioncoefficient.Totalpalliative
prognosticscorescanrangebetween0and17.5anddefinethree
prognostic categories representing different probabilities of
surviving 30 days (<30%, 30-70%, and >70%). The palliative
prognostic score has been subsequently validated in several
clinicalstudies.
33-37Oneofitsdrawbacksistheheavyweighting
that is attributed to the clinician’s prediction of survival; the
partialscorefortheclinician’spredictioncanrepresent8.8/17.5
(49%) of the total score. Moreover, clinicians are required to
provide an unrealistically accurate prognostic estimate in two
week intervals. A patient who is expected to live for three to
four weeks thus scores 1.5 points more than a patient expected
to survive for five to six weeks and 3.5 points more than a
patient expected for live for seven to 10 weeks. Most clinicians
are reluctant to offer prognostic estimates with this degree of
precision. Another limitation of the palliative prognostic score
is the difficulty of converting the prognostic categories into
meaningful clinical information. How should a clinician (or
patient)interprettheinformationthattheyhavea30-70%chance
of surviving 30 days? PiPS overcomes these problems.
Meaning of study
The PiPS-A score can be calculated for any patient with
advanced cancer who is no longer receiving disease modifying
treatment,anditisatleastasgoodas,butnotsignificantlybetter
than, a clinician’s estimate of survival. The PiPS-B prognostic
estimate requires a blood test, but it is statistically significantly
better than the best uni-professional estimate of survival.
Although the absolute increase in prognostic accuracy is not
large, PiPS-B shares with PiPS-A the advantages of being
independentoftheclinician’sopinionandofbeingreproducible
andcomparableacrosssettings.Inaclinicalcontext,webelieve
that PiPS estimates would usually be used to inform and
augment clinicians’ own subjective estimates (rather than to
replace them). However, our study suggests that the PiPS-B
estimate of survival could now act as the “benchmark” against
whichnewprognostictoolsareassessed.Wehopethatthiswill
act as the first step in an incremental process of improving
prognostic accuracy as novel indicators are tested against, and
then incorporated into, the PiPS models.
Unanswered questions and further research
Although the PiPS prognostic scores have been developed in a
robust fashion, further validation work is needed before the
scales can be recommended for use in routine clinical practice.
The clinical information needed to calculate the PiPS scores is
easilyobtained.However,althoughthescorescanbecalculated
with minimal arithmetical effort, they cannot be directly or
easily calculated at the bedside. We have therefore produced a
simplecomputerbasedinterfaceforthePiPSinstruments.
38We
plan to develop this tool so that the algorithms will be available
across a range of platforms and will allow users to rapidly
convert clinical data into prognostic estimate categories.
As previously described, we have tested the PiPS models by
usingcrossvalidationtechniques,buttheiraccuracyhasnotyet
been assessed in independent datasets. The validation of
prognostictoolsemergedasthehighestpriorityamongclinicians
and researchers in a recent consensus workshop on
prognostication.
39 We are planning a large prospective
multicentre external validation study to include an assessment
ofusers’(clinicians,patients,andcarers)viewsaboutthemodels
and the best way for data to be presented to accurately reflect
the degree of uncertainty inherent in the models.
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RESEARCHWhat is already known on this topic
Prognostic information is valued by patients, carers, and healthcare professionals
Clinicians’ predictions of survival are the mainstay of current practice but are unreliable, over-optimistic, and subjective
What this study adds
Two prognostic scores have been created, both of which are able to predict whether patients will survive for “days,”
“weeks,” or “months”
Both scores are independent of clinicians’ subjective estimates of survival, and both are at least as accurate as a
clinician’s estimate
One of the prognostic scores (which requires a blood test) is significantly better than an individual doctor’s or nurse’s
prediction, but neither scale is significantly more accurate than a multi-professional estimate of survival
research and development approval were obtained for participating
units. Exemption from Section 60 of the Health and Social Care Act
(2001) was obtained from the Patient Information Advisory Group (PIAG).
This allows the records of incompetent patients to be accessed without
explicit consent so that study variables can be recorded and patients
“flagged” for mortality purposes with the NHS Information Centre.
Consent was given by competent patients and assent by the
relatives/carers of incompetent patients.
Data sharing: No additional data available.
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RESEARCHTables
Table 1| Characteristics of study sample. Values are numbers (percentages) unless stated otherwise
Value (n=1018) Characteristic
775 (76.1) Patient competent
557 (54.7) Male sex
Location:
123 (12.1) Home
182 (17.9) Hospital
701 (68.9) Hospice
25 (2.5) Other
524 (51.5) Marital status single
904 (88.8) White British ethnicity
Site of primary cancer:
305 (30.0) Digestive organs
238 (23.4) Respiratory/intrathoracic
103 (10.1) Independent multiple sites/unknown primary/other
74 (7.3) Breast
71 (7.0) Male genital organs (including prostate)
68 (6.7) Urinary tract
52 (5.1) Female genital organs
38 (3.7) Eye/brain/central nervous system
36 (3.5) Lymphatic/haematological
33 (3.2) Oropharynx/mouth
Site of metastatic disease:
684 (67.2) Anywhere
276 (27.1) Liver
268 (26.3) Bone
213 (20.9) Lung
90 (8.8) Brain
82 (8.1) Other/not recorded
68 (6.7) Ascites
50 (4.9) Pleural effusion
25 (2.5) Adrenal
20 (2.0) Skin
3 (0.3) Pericardial effusion
209 (20.5) Regional lymph node spread
101/1017 (9.9) Receiving hormone therapy
32/1017 (3.1) Receiving palliative radiotherapy
(n=1011) Charlton comorbidity score:
453 (44.8) 0
395 (39.1) 1
117 (11.6) 2
46 (4.5) 3
Drugs:
688/1017 (67.6) Strong opioids
449/1013 (44.3) Corticosteroids
99/1012 (9.8) Bisphosphonates
173/1015 (17.0) Antibiotics
693/998 (69.4) Weight loss in previous month
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RESEARCHTable 1 (continued)
Value (n=1018) Characteristic
137/1015 (13.5) Clinically apparent ascites
391/1015 (38.5) Clinically apparent pitting oedema
663/1011 (65.6) Lack of appetite
280/1015 (27.6) Breathlessness
626/1014 (61.7) Dry mouth
292/1014 (28.8) Difficulty swallowing
879/1014 (86.7) Pain
879/1015 (86.6) Tired
(n=1015) Eastern Co-operative Oncology Group score:
2 (0.2) 0
81 (8.0) 1
216 (21.3) 2
435 (42.9) 3
281 (27.7) 4
(n=1015) Global health status:
125 (12.3) 1
154 (15.2) 2
336 (33.1) 3
290 (28.6) 4
94 (9.3) 5
16 (1.6) 6
0 (0) 7
(n=1009) Mental test score:
233 (23.1) ≤3
776 (76.9) >3
86 (15.6) Mean (SD) pulse rate (beats/min)
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RESEARCHTable 2| Mean (SD) laboratory results for study sample
Result Variable
Full blood count
11.04 (2.0) (n=786) Haemoglobin (g/dL)
88.75 (7.8) (n=779) Mean cell volume (fl)
11.96 (7.3) (n=786) White blood count (×10
9/L)
10.55 (10.3) (n=783) Neutrophil count (×10
9/L)
1.41 (2.0) (n=783) Lymphocyte count (×10
9/L)
333.9 (162.3) (n=786) Platelets (×10
9/L)
Biochemistry
135.75 (5.0) (n=797) Sodium (mmol/L)
4.44 (0.8) (n=784) Potassium (mmol/L)
98.2 (7.1) (n= 628) Chloride (mmol/L)
26.0 (4.6) (n=610) Bicarbonate (mmol/L)
9.25 (7.0) (n=798) Urea (mmol/L)
88.3 (66.5) (n=797) Creatinine (µmol/L)
6.79 (3.0) (n=611) Glucose (mmol/L)
16.1 (38.9) (n=765) Bilirubin (µmol/L)
36.0 (58.1) (n= 761) Alanine transaminase (U/L)
263.9 (340.0) (n=778) Alkaline phosphatise (U/L)
29.4 (6.8) (n=787) Albumin (g/L)
2.18 (0.2) (n=749) Calcium (mmol/L)
0.84 (0.1) (n=627) Magnesium (mmol/L)
82.0 (80.1) (n=696) C reactive protein (mg/L)
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RESEARCHTable 3| PiPS-A backwards elimination models (n=1018)
PiPS-A56† PiPS-A14* Variable
P value Odds ratio (95% CI) P value Odds ratio (95% CI)
0.001 2.341 (1.445 to 3.794) <0.001 3.571 (2.301 to 5.541) Mental test score >3
<0.001 0.978 (0.967 to 0.988) <0.001 0.977 (0.965 to 0.989) Pulse rate
0.024 0.666 (0.467 to 0.949) 0.044 0.608 (0.374 to 0.987) Presence of distant metastases
0.003 0.552 (0.374 to 0.815) 0.018 0.584 (0.374 to 0.912) Site of metastases—liver
0.039 0.803 (0.652 to 0.989) <0.001 0.559 (0.430 to 0.754) ECOG score
<0.001 1.732 (1.449 to 2.071) <0.001 1.567 (1.269 to 1.935) Global heath score
0.01 0.657 (0.477 to 0.903) 0.001 0.463 (0.291 to 0.736) Loss of appetite
– – 0.027 1.681 (1.061 to 2.662) Site of metastases—bone
– – 0.018 0.622 (0.419 to 0.922) Difficulty breathing
– – 0.009 0.583 (0.389 to 0.873) Difficulty swallowing
0.033 1.853 (1.050 to 3.269) – – Primary breast cancer
<0.001 4.379 (2.375 to 8.085) – – Primary male genital cancer (including prostate)
0.002 0.601 (0.433 to 0.834) – – Weight loss
ECOG=Eastern Co-operative Oncology Group.
*Area under curve=0.866.
†Area under curve=0.793.
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RESEARCHTable 4| PiPS-B backwards elimination models (n=796)
PiPS-B56† PiPS-B14*
Variable P value Odds ratio (95% CI) P value Odds ratio (95% CI)
0.044 0.987 (0.974 to 0.999) 0.033 0.983 (0.968 to 0.999) Pulse rate
0.026 0.958 (0.923 to 0.995) <0.001 0.941 (0.914 to 0.969) White blood count
0.017 1.001 (1.000 to 1.003) 0.001 1.003 (1.001 to 1.004) Platelets
0.001 0.940 (0.908 to 0.974) <0.001 0.944 (0.919 to 0.970) Urea
<0.001 0.993 (0.990 to 0.996) <0.001 0.994 (0.992 to 0.999) C reactive protein
<0.001 1.606 (1.339 to 1.927) 0.003 1.482 (1.145 to 1.919) Global heath score
– – 0.007 0.996 (0.993 to 0.999) Alanine transaminase
– – 0.004 2.591 (1.344 to 4.997) Mental test score >3
– – 0.004 0.434 (0.247 to 0.761) Distant metastases
– – 0.006 2.153 (1.240 to 3.739) Site of metastases—bone
– – 0.014 0.507 (0.295 to 0.874) Lack of appetite
– – 0.005 0.588 (0.407 to 0.849) ECOG score
0.025 0.969 (0.944 to 0.996) – – Neutrophils
0.032 1.177 (1.014 to 1.366) – – Lymphocytes
0.001 0.999 (0.998 to 0.999) – – Alkaline phosphatase
0.009 1.041 (1.010 to 1.073) – – Albumin
<0.001 4.757 (2.354 to 9.610) – – Primary male genital cancer (including prostate)
0.012 0.510 (0.301 to 0.863) – – Tired
ECOG=Eastern Co-operative Oncology Group
*Area under curve=0.859.
†Area under curve=0.809.
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RESEARCHTable 5| Comparison of PiPS-A models against clinicians’ predictions
P value for comparison of model A with:
Linear weighted κ
Absolute
agreement
(%)
Actual survival
Predictions
Multi-professional
predictions Nurses’ predictions Doctors’ predictions Total Months+ Weeks Days
Doctor
156 3 16 137 Days
294 86 126 82 Weeks
379 204 139 36 Months+
0.284 0.154 NA 0.442 56.3 829 293 281 255 Total
Nurse
161 7 19 135 Days
279 79 116 84 Weeks
514 276 186 52 Months+
0.007 NA 0.154 0.412 55.2 954 362 321 271 Total
Multi-professional
168 4 17 147 Days
324 92 136 96 Weeks
495 284 176 35 Months+
NA 0.007 0.284 0.457 57.5 987 380 329 278 Total
PiPS-A models
197 16 32 149 Days
413 136 191 86 Weeks
344 229 93 22 Months+
0.515 0.249 0.958 0.470 (0.441*) 59.6 (57.3*) 954 381 316 257 Total
NA=not applicable.
*Adjusted for over-optimism by using bootstrap.
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RESEARCHTable 6| Comparison of PiPS-B models against clinicians’ predictions
P value for comparison of model B with:
Linear weighted κ
Absolute
agreement
(%)
Actual survival
Predictions
Multi-professional
predictions Nurses’ predictions Doctors’ predictions Total Months+ Weeks Days
Doctor
62 1 12 49 Days
254 79 113 62 Weeks
340 183 124 33 Months+
0.385 0.304 NA 0.322 52.6 656 263 249 144 Total
Nurse
69 6 13 50 Days
228 69 102 57 Weeks
454 241 164 49 Months+
0.029 NA 0.304 0.293 52.3 751 316 279 156 Total
Multi-professional
68 1 13 54 Days
274 84 118 72 Weeks
433 244 154 35 Months+
NA 0.029 0.385 0.336 53.7 775 329 285 161 Total
PiPS-B models
69 5 18 46 Days
305 88 159 58 Weeks
272 192 69 11 Months+
0.188 0.012 0.0135 0.436 (0.373*) 61.5 (57.3*) 646 285 246 115 Total
NA=not applicable.
*Adjusted for over-optimism by using bootstrap.
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RESEARCHFigures
Fig 1 Selection of study sample
Fig 2 Kaplan-Meier survival curves for PiPS-A models. Graph shows survival curves for three prognostic groups identified
by PiPS-A scores. Vertical lines indicate survival at specific “cut-off points” of 14 and 56 days. Harrell’s C index is defined
as proportion of pairs of participants in which predictions and outcomes are concordant, and C=0.6894 indicates that PiPS-A
scores can correctly order survival times for pairs of participants 68.9% of time
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RESEARCHFig 3 Kaplan-Meier survival curves for PiPS-B models. Graph shows survival curves for three prognostic groups identified
by PiPS-B scores. Vertical lines indicate survival at specific “cut-off points” of 14 and 56 days. Harrell’s C index is defined
as proportion of pairs of participants in which predictions and outcomes are concordant, and C=0.6745 indicates that PiPS-B
scores can correctly order survival times for pairs of participants 67.5% of time
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